Medicine · Français

Will the FDA approve lorundrostat for hypertension?

deadline 2026-12-22 confidence medium tier 4 evidence
63%Asturna estimate

Resolution criterion

Resolves YES if the FDA publishes an approval (Drugs@FDA or an official Mineralys Therapeutics press release) for lorundrostat in adults with hypertension on or before 22 December 2026. A complete response letter, a postponement of the PDUFA date, or the absence of a decision count as no. This resolves against approval specifically for hypertension (any severity, including resistant hypertension); an approval for an unrelated indication (e.g. obstructive sleep apnea only) does not count as yes.

Verified starting state

NDA accepted, PDUFA target action date 22 December 2026. Aldosterone synthase inhibitor, a mechanism class not yet approved in the US for hypertension. A related Phase 2 trial in obstructive sleep apnea (Explore-OSA) reported topline results that fell short, announced the same day as the NDA acceptance — unrelated to the hypertension indication under review. (Mineralys Therapeutics press release / SEC filing, 6 March 2026)

What pushes it up

What pushes it down

What would move this number most

Whether the FDA identifies safety issues (such as hyperkalemia or adrenal insufficiency) or requests additional clinical/manufacturing data during the final review phase before the December 22, 2026 PDUFA date.

How this number is built

Deadline2026-12-22
Base rate64%
Best evidencetier 4 · 0 article(s) used
Independent runs62 · 63 (spread 1 pts)
Confidencemedium
Evidence capnot triggered
Last revised2026-10-18 09:09
Modelgemini-3.6-flash

Probability history

2026-10-18 09:09 63% 103 article(s) on file · gemini-3.6-flash
  • What pushes it up. The FDA accepted the NDA for lorundrostat in hypertension with a PDUFA action date set for December 22, 2026 [tier 1].
  • What pushes it down. Lorundrostat belongs to a novel class (aldosterone synthase inhibitors) not yet approved in the US for hypertension, presenting safety and efficacy scrutiny around hyperkalemia and off-target steroidogenesis suppression [tier 1].
  • What pushes it down. Topline results from a Phase 2 trial (Explore-OSA) in a secondary indication fell short, highlighting potential trial variability or safety nuances [tier 1].
  • What would move this number most. Whether the FDA identifies safety issues (such as hyperkalemia or adrenal insufficiency) or requests additional clinical/manufacturing data during the final review phase before the December 22, 2026 PDUFA date.
2026-10-17 09:07 57% 97 article(s) on file · gemini-3.8-flash
  • What pushes it up. Lorundrostat's NDA for hypertension is actively under FDA review with an established PDUFA target action date of 22 December 2026, with no CRL or review extension reported to date [tier 1].
  • What pushes it down. The resolution criteria specify that any postponement of the PDUFA date counts as a NO, and standard three-month major amendment extensions occur in roughly 10-15% of novel mechanism reviews [tier 2].
  • What pushes it down. Lorundrostat represents a first-in-class aldosterone synthase inhibitor, a novel mechanism class not previously approved in the US for hypertension, carrying elevated regulatory and safety scrutiny [tier 1].
  • What would move this number most. Whether the FDA issues a standard three-month PDUFA extension for chemistry, manufacturing, and controls (CMC) or labeling amendments before 22 December 2026.
2026-10-14 12:06 60% 83 article(s) on file · gemini-3-flash-preview
  • What pushes it up. The FDA has accepted the NDA for lorundrostat with a PDUFA target action date of December 22, 2026, which aligns with the resolution deadline [tier 1].
  • What pushes it up. Aldosterone synthase inhibition is a scientifically validated target for hypertension, even if this is the first of its class seeking US approval [tier 1].
  • What pushes it down. A related Phase 2 trial (Explore-OSA) for obstructive sleep apnea failed to meet its topline results, which may indicate limitations in the drug's broader clinical profile [tier 1].
  • What pushes it down. As a first-in-class mechanism, lorundrostat faces higher regulatory scrutiny and a higher risk of a Complete Response Letter or review extension [tier 1, tier 2].
  • What pushes it down. Manufacturing site issues or the need for additional data can lead to PDUFA extensions, which would result in a NO resolution under these criteria [tier 2].
  • What would move this number most. The primary uncertainty is whether the FDA will require an Advisory Committee meeting or identify safety/manufacturing concerns during the final two months of the review cycle.
2026-10-13 12:09 59% 83 article(s) on file · gemini-3-flash-preview
  • What pushes it up. The FDA has accepted the NDA for lorundrostat with a specific PDUFA target action date of December 22, 2026 [1].
  • What pushes it down. Lorundrostat uses a novel mechanism (aldosterone synthase inhibitor) not yet approved in the US for hypertension, which typically attracts higher regulatory scrutiny [1].
  • What pushes it down. A related Phase 2 trial (Explore-OSA) for obstructive sleep apnea failed to meet its topline results, which may raise questions about the drug's broader efficacy or safety profile [1].
  • What pushes it down. The PDUFA date is exactly on the resolution deadline; any review extension, which is common for novel mechanisms or manufacturing issues, would result in a 'No' resolution [1, 18].
  • What would move this number most. The primary uncertainty is whether the FDA will identify any clinical or manufacturing issues requiring a Complete Response Letter or a review extension, especially given the novel mechanism and the failure of the related OSA trial.
2026-10-12 12:01 57% 74 article(s) on file · gemini-flash-latest
  • What pushes it up. Lorundrostat's NDA has been accepted for review with an assigned PDUFA target action date of 22 December 2026, and review remains on track [tier 1].
  • What pushes it down. The resolution criteria specify that any postponement of the PDUFA date counts as 'no'; first-cycle approval statistics include reviews extended by 3-month major amendments, making the on-time probability strictly lower than the 64% base rate [tier 1].
  • What pushes it down. As a first-in-class aldosterone synthase inhibitor for hypertension, regulatory scrutiny on selectivity and safety (e.g., hyperkalemia and adrenocortical effects) presents elevated risk of CRL or requests for additional analyses [tier 1].
  • What pushes it down. Mineralys Therapeutics is an emerging biotech managing its initial NDA filing, which historically carries slightly higher rates of review delay or manufacturing/data queries than large pharmaceutical sponsors [tier 1].
  • What would move this number most. Whether the FDA issues a decision on or before the exact PDUFA date of 22 December 2026 or triggers a standard 3-month clock extension for major amendments.
2026-10-11 09:15 59% 74 article(s) on file · gemini-3.7-flash
  • What pushes it up. Lorundrostat's NDA for hypertension was accepted with an established PDUFA target action date of 22 December 2026 [tier 1].
  • What pushes it up. No negative regulatory developments, complete response letters, or safety warnings have been reported regarding the hypertension program as of October 2026 [tier 1].
  • What pushes it down. Lorundrostat is an aldosterone synthase inhibitor, a novel mechanism class not previously approved in the US for hypertension, carrying elevated safety and regulatory scrutiny [tier 1].
  • What pushes it down. The resolution criteria strictly require approval on or before 22 December 2026, meaning any standard three-month PDUFA review extension pushes the decision into 2027 and resolves as No [tier 1].
  • What would move this number most. Whether the FDA requests additional clinical or chemistry, manufacturing, and controls (CMC) data that triggers a three-month PDUFA extension or a Complete Response Letter.
2026-10-08 09:11 66% 57 article(s) on file · gemini-3-flash-preview
  • What pushes it up. The FDA accepted the NDA for lorundrostat with a PDUFA target action date of December 22, 2026, which aligns with the resolution deadline [1].
  • What pushes it up. Mineralys Therapeutics has been actively raising funds and preparing for a commercial launch, signaling corporate confidence in the upcoming regulatory decision [2].
  • What pushes it up. There have been no reports of FDA-mandated delays, advisory committee meetings, or major safety concerns since the NDA was accepted in March 2026 [1, 2].
  • What pushes it down. The PDUFA date is the final day of the resolution window; any 3-month extension or minor administrative delay would result in a 'No' resolution [1].
  • What pushes it down. Lorundrostat is an aldosterone synthase inhibitor, a mechanism class not yet approved in the US for hypertension, which may invite higher regulatory scrutiny [1].
  • What pushes it down. A related Phase 2 trial for obstructive sleep apnea failed to meet its topline results, which could potentially raise questions about the drug's broader efficacy profile [1].
  • What would move this number most. The primary uncertainty is whether the FDA will require a standard 3-month extension to review the new mechanism of action, which would push the decision past the December 22 deadline.
2026-10-02 09:10 67% 31 article(s) on file · openai/gpt-oss-120b (Groq)
  • What pushes it up. Company’s public moves suggest confidence in an imminent hypertension approval (Endpoints News, tier 2)
  • What pushes it up. NDA acceptance and a set PDUFA target date indicate FDA is proceeding toward a decision (hand‑verified tier 1)
  • What pushes it down. Recent Phase 2 OSA trial failed, raising possible safety/efficacy concerns for the same molecule (hand‑verified tier 1)
  • What pushes it down. Base‑rate for new‑mechanism drugs is only 64%, reflecting inherent uncertainty
  • What would move this number most. The FDA’s final decision at the PDUFA date – whether it issues approval or a complete response letter.
2026-10-01 09:01 65% 26 article(s) on file · openai/gpt-oss-20b (Groq)
  • What pushes it up. NDA acceptance and scheduled PDUFA date indicate a review will occur, raising the likelihood of approval. [1]
  • What pushes it down. No tier 1 or 2 evidence of approval or positive data for hypertension, and the mechanism is new with no prior approvals, lowering confidence. [4]
  • What would move this number most. Whether the FDA will find the efficacy and safety data sufficient for approval; a rejection would drop the probability dramatically.
2026-09-30 17:00 60% 17 article(s) on file · openai/gpt-oss-20b (Groq)
  • What pushes it up. NDA acceptance and a PDUFA target date of 22 Dec 2026 indicate the FDA has moved the application forward (tier 2).
  • What pushes it down. No hypertension efficacy data or safety signals have been reported; the mechanism is novel and has no prior approvals, lowering confidence in a favorable outcome (tier 2).
  • What would move this number most. The availability and quality of hypertension trial data and the safety profile of lorundrostat will most influence the approval likelihood.